68 related articles for article (PubMed ID: 23590991)
1. Autoimmune thyroid disease elicited by NY-ESO-1 vaccination.
Vita R; Guarneri F; Agah R; Benvenga S
Thyroid; 2014 Feb; 24(2):390-4. PubMed ID: 23590991
[TBL] [Abstract][Full Text] [Related]
2. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.
Dutoit V; Taub RN; Papadopoulos KP; Talbot S; Keohan ML; Brehm M; Gnjatic S; Harris PE; Bisikirska B; Guillaume P; Cerottini JC; Hesdorffer CS; Old LJ; Valmori D
J Clin Invest; 2002 Dec; 110(12):1813-22. PubMed ID: 12488431
[TBL] [Abstract][Full Text] [Related]
3. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.
Gnjatic S; Nagata Y; Jager E; Stockert E; Shankara S; Roberts BL; Mazzara GP; Lee SY; Dunbar PR; Dupont B; Cerundolo V; Ritter G; Chen YT; Knuth A; Old LJ
Proc Natl Acad Sci U S A; 2000 Sep; 97(20):10917-22. PubMed ID: 11005863
[TBL] [Abstract][Full Text] [Related]
4. First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1.
Mahipal A; Ejadi S; Gnjatic S; Kim-Schulze S; Lu H; Ter Meulen JH; Kenney R; Odunsi K
Cancer Immunol Immunother; 2019 Jul; 68(7):1211-1222. PubMed ID: 31069460
[TBL] [Abstract][Full Text] [Related]
5. Multiplex genetic manipulations in Clostridium butyricum and Clostridium sporogenes to secrete recombinant antigen proteins for oral-spore vaccination.
Zhang Y; Bailey TS; Hittmeyer P; Dubois LJ; Theys J; Lambin P
Microb Cell Fact; 2024 Apr; 23(1):119. PubMed ID: 38659027
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.
Somaiah N; Chawla SP; Block MS; Morris JC; Do K; Kim JW; Druta M; Sankhala KK; Hwu P; Jones RL; Gnjatic S; Kim-Schulze S; Tuballes K; Yishak M; Lu H; Yakovich A; Ter Meulen J; Chen M; Kenney RT; Bohac C; Pollack SM
Oncoimmunology; 2020 Nov; 9(1):1847846. PubMed ID: 33312760
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.
Kawai A; Ishihara M; Nakamura T; Kitano S; Iwata S; Takada K; Emori M; Kato K; Endo M; Matsumoto Y; Kakunaga S; Sato E; Miyahara Y; Morino K; Tanaka S; Takahashi S; Matsuo F; Matsumine A; Kageyama S; Ueda T
Clin Cancer Res; 2023 Dec; 29(24):5069-5078. PubMed ID: 37792433
[TBL] [Abstract][Full Text] [Related]
8. Histological Assessment of Synovial Sarcoma Before and After TCR-T Cell Therapy and Cryoablation: A Case Report.
Asanuma K; Ishihara M; Nakamura T; Uchida K; Hagi T; Kageyama S; Shiku H; Sudo A
Anticancer Res; 2023 Dec; 43(12):5737-5748. PubMed ID: 38030212
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune/Inflammatory Syndrome Induced by Adjuvants and Thyroid Autoimmunity.
Watad A; David P; Brown S; Shoenfeld Y
Front Endocrinol (Lausanne); 2016; 7():150. PubMed ID: 28167927
[TBL] [Abstract][Full Text] [Related]
10. Two Cases of Graves' Disease Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome Induced by Adjuvants.
Vera-Lastra O; Ordinola Navarro A; Cruz Domiguez MP; Medina G; Sánchez Valadez TI; Jara LJ
Thyroid; 2021 Sep; 31(9):1436-1439. PubMed ID: 33858208
[No Abstract] [Full Text] [Related]
11. Severe thyrotoxicosis induced by tislelizumab: a case report and literature review.
Huo L; Wang C; Ding H; Shi X; Shan B; Zhou R; Liang P; Hou J
Front Oncol; 2023; 13():1190491. PubMed ID: 37849819
[TBL] [Abstract][Full Text] [Related]
12. Amino acid sequence homology between thyroid autoantigens and central nervous system proteins: Implications for the steroid-responsive encephalopathy associated with autoimmune thyroiditis.
Benvenga S; Antonelli A; Fallahi P; Bonanno C; Rodolico C; Guarneri F
J Clin Transl Endocrinol; 2021 Dec; 26():100274. PubMed ID: 34849350
[TBL] [Abstract][Full Text] [Related]
13. Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Paderi A; Giorgione R; Giommoni E; Mela MM; Rossi V; Doni L; Minervini A; Carini M; Pillozzi S; Antonuzzo L
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670634
[TBL] [Abstract][Full Text] [Related]
14. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities.
Xu Y; Fu Y; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():2023. PubMed ID: 33123120
[TBL] [Abstract][Full Text] [Related]
15. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Kurimoto C; Inaba H; Ariyasu H; Iwakura H; Ueda Y; Uraki S; Takeshima K; Furukawa Y; Morita S; Yamamoto Y; Yamashita S; Katsuda M; Hayata A; Akamatsu H; Jinnin M; Hara I; Yamaue H; Akamizu T
Cancer Sci; 2020 May; 111(5):1468-1477. PubMed ID: 32086984
[TBL] [Abstract][Full Text] [Related]
16. Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer.
Koyama J; Horiike A; Yoshizawa T; Dotsu Y; Ariyasu R; Saiki M; Sonoda T; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Ninomiya H; Ishikawa Y; Nishio M
J Thorac Dis; 2019 May; 11(5):1919-1928. PubMed ID: 31285885
[TBL] [Abstract][Full Text] [Related]
17. Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody.
Shiba M; Inaba H; Ariyasu H; Kawai S; Inagaki Y; Matsuno S; Iwakura H; Yamamoto Y; Nishi M; Akamizu T
Intern Med; 2018 Jul; 57(14):2029-2034. PubMed ID: 29491310
[TBL] [Abstract][Full Text] [Related]
18. Thyroid dysfunctions secondary to cancer immunotherapy.
Chalan P; Di Dalmazi G; Pani F; De Remigis A; Corsello A; Caturegli P
J Endocrinol Invest; 2018 Jun; 41(6):625-638. PubMed ID: 29238906
[TBL] [Abstract][Full Text] [Related]
19. Thyroid Autoimmunity and Lichen.
Guarneri F; Giuffrida R; Di Bari F; Cannavò SP; Benvenga S
Front Endocrinol (Lausanne); 2017; 8():146. PubMed ID: 28701998
[TBL] [Abstract][Full Text] [Related]
20. Thyrotropin Receptor Epitope and Human Leukocyte Antigen in Graves' Disease.
Inaba H; De Groot LJ; Akamizu T
Front Endocrinol (Lausanne); 2016; 7():120. PubMed ID: 27602020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
